Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. On March 12, 2012, it acquired a 19.9% minority equity investment in Pele Nova Biotecnologia S.A. In April 2013, Valeant Pharmaceuticals International Inc acquired the entire share capital of Obagi Medical Products Inc.
|Headquarters||2150 St. Elzear Blvd., West Laval|
MONTREAL, QC, Canada H7L 4A8
|Chairman of the Board, Chief Executive Officer||J. Michael Pearson|
|Chief Financial Officer, Executive Vice President, Director||Howard Schiller|
|Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development||Robert Chai-Onn|
|Executive Vice President, Company Group Chairman||Laizer Kornwasser|
|Executive Vice President - Administration, Chief Human Capital Officer||Brian Stolz|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||303.8M||Book Value||$12.23|
|Annual Dividend Rate||--||Price/Sales (TTM)||6.4|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||24.8x|
|Pay Date||1/1/01||Operating Margin||2.50%|
*GAAP = prior to non-GAAP analyst adjusted earnings.